Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth and by stopping blood flow to the tumor. It is not yet known which regimen of
celecoxib is more effective in treating breast cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of celecoxib
in treating women who have metastatic or recurrent breast cancer